Predictive value of hepcidin and HIF1α protein levels for iron deposition in β-thalassemia.

To investigate differences in the relative expression levels of the novel iron regulatory erythroid factors hepcidin, HIF1α, HIF2α, and ERFE in children with β-thalassemia exhibiting different serum ferritin (SF) levels. A total of 93 children with β-thalassemia were enrolled from the First Affiliated Hospital of Guangxi Medical University between October 2022 and May 2023. Participants were categorized based on their SF levels: 64 with SF>1000 μg/L and 29 with SF<1000 μg/L. ELISA assays were used to determine the relative expression levels of hepcidin, HIF1α, HIF2α, and ERFE between the two groups. The odds ratio (OR) for hepcidin protein was 0.999 (p<0.05), with an area under the curve (AUC) of 0.650 (p<0.05). Sensitivity and specificity were 46.9% and 82.8%, respectively, with a cutoff value of 1.710 ng/mL. The OR for HIF1α protein was 2.352 (p<0.05), with an AUC of 0.703 (p<0.05). Sensitivity and specificity were 43.8% and 89.7%, respectively, with a cutoff value of 2.115 ng/mL. Lower hepcidin levels and higher HIF1α levels were associated with an increased likelihood of iron deposition in children with β-thalassemia.

conclusionsHepcidin and HIF1α appear to be promising biomarkers for assessing iron deposition in β-thalassemia. Therefore, it is necessary to further investigate their potential as therapeutic targets for β-thalassemia and other iron deposition related disorders. WHAT IS KNOWN: • Patients with transfusion-dependent thalassemia require iron chelation therapy. • Hepcidin and HIF1α are recently identified iron regulatory erythroid factors. WHAT IS NEW: •In children with β-thalassemia, hepcidin protein levels are negatively correlated with iron deposition, whereas HIF1α protein levels are positively correlated. • Hepcidin and HIF1α may serve as novel biomarkers for iron deposition in β-thalassemia, providing potential value in evaluating iron deposition severity when inflammation and infection are excluded.